Regulatory

BRIEF—Health Canada added approval for Tafinlar plus Mekinist combo

December 10, 2018

Source: The Pharma Letter, December 2018 Pharma regulator Health Canada has approved the use of a combination of two Novartis cancer therapies as targeted treatment to prevent recurrence of melanoma…

European Commission approves BRAFTOVI and MEKTOVI to treat advanced BRAF-mutant melanoma

October 29, 2018

Melanoma News, Regulatory, Publications

Source: Hospital Healthcare Europe, October 2018 The European Commission (EC) had approved the use of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) to treat adults with advanced BRAF-mutant melanoma. The EC’s decision is…

NICE turns down Opdivo for adjuvant melanoma therapy

October 3, 2018

Melanoma News, Regulatory

England’s cost effectiveness watchdog NICE has decided not to recommend use of the PD-1 inhibitor

Half of European clinical trials haven’t reported results

September 28, 2018

Melanoma News, Regulatory, Of Interest

A new interactive website shows that 49% of clinical trials on the EU clinical trials register have not reported results.

Regulatory

BRIEF—Health Canada added approval for Tafinlar plus Mekinist combo

European Commission approves BRAFTOVI and MEKTOVI to treat advanced BRAF-mutant melanoma

NICE turns down Opdivo for adjuvant melanoma therapy

Half of European clinical trials haven’t reported results

MRV News

Melanoma News

Archive

Our Partners

Melanoma Research Victoria

Quick Links